Summary

  • Akamai’s warrant does not hand Anthropic 5% of the company today. Forty per cent of the warrant vests on a first payment under Project Plan 3; the remaining three tranches require additional, signed commitments of contractual value.
  • Even after vesting, Anthropic must pay cash to exercise. The preferred shares carry no ordinary voting rights while held inside Anthropic’s group, but they retain economic participation and can create dilution after exercise.
  • Akamai says the expected value of roughly 3.1 million common-equivalent shares reduces transaction revenue. Investors should read the warrant and the service commitment as one commercial package, without treating management’s expectation as proof that a trigger has occurred.

A five-per-cent headline invites a cap-table reading. The contract asks a more useful question first: what must Anthropic do before any part of the warrant can be bought? Akamai issued a warrant on 18 September 2026 for as many as 387,051 Series B Non-Voting Convertible Preferred shares. Each is initially convertible into 20 common shares, or 7,741,020 common-equivalent shares in total. Akamai describes that ceiling as approximately 5% of common shares outstanding. It is a maximum tied to future conditions, not a report that Anthropic already owns those common shares.

The first condition is deliberately different from the next three. Forty per cent of the warrant vests when Anthropic or an affiliate makes its first payment under Project Plan 3. After that, three additional tranches of 20% each depend on definitive expansion agreements: cumulative additional contractual value must reach US$3 billion, US$6 billion and US$9 billion. Those later thresholds are commitments above the value in Project Plans 2 and 3. A forecast, a discussion about more capacity or a rise in usage does not substitute for an agreement that commits the additional value.

That structure makes the warrant an expansion incentive attached to a services relationship. Anthropic receives a chance to acquire Akamai shares as the relationship crosses contractual thresholds; Akamai receives a mechanism to reward a larger commitment without issuing the maximum number of shares at the outset. The incentives point in the same direction only at the level of signed commercial scope. They do not prove that either party will earn an attractive return from each incremental dollar, or that a commitment will translate into a particular level of consumption.

The underlying plans remain subject to delivery, service-availability and termination provisions.

The right is also not free stock. Each preferred share carries a US$2,226.60 exercise price and initially represents 20 common shares, equivalent to US$111.33 per common share. Anthropic must pay the aggregate price in cash by wire; the agreement excludes cashless or net settlement. A vested warrant is therefore an option whose practical value depends partly on Akamai’s share price during the exercise window. If the market price is below the strike, immediate exercise is unattractive; if it is above, exercise can turn the right into an economic interest. Neither outcome changes the fact that vesting and exercise are separate steps.

The preferred form limits one kind of influence while preserving another. Series B holders have no voting rights except where Delaware law requires them, and Anthropic cannot elect to convert the shares into common stock while it or a wholly owned subsidiary holds them. Conversion is tied to an allowed transfer outside that group or a change in holder status. Yet “non-voting” does not mean “without economics”: the preferred shares participate in dividends and other distributions on an as-converted basis, and carry a small liquidation preference before that participation.

The design keeps the warrant from functioning as ordinary voting stock in Anthropic’s hands while still giving it financial value.

The accounting presentation makes that value part of the price investors need to assess. Akamai’s 24 September investor deck says approximately 3.1 million common-equivalent shares, or about 2% of shares outstanding, are expected to vest with the announced commercial arrangement. It says the fair value of those shares reduces total revenue and is reflected in the US$11.6 billion commitment. The deck also describes dilution using the treasury-stock method: it assumes expected-to-vest warrants are exercised and uses the proceeds to repurchase shares at the current price.

Akamai says modeled dilution rises if its share price increases or if additional commitments are signed. These are management’s estimates; the public filing does not establish that the first-payment trigger has already been met.

The headline therefore compresses three different measurements into one number: a maximum share count, a conditional right to purchase, and an accounting estimate of customer consideration. A reader evaluating the deal should not add 5% to today’s ownership table or treat US$11.6 billion as revenue already earned. The useful evidence will be a payment-trigger disclosure, signed expansion agreements at the stated thresholds, and later reporting that separates the service economics from the fair value of the warrant.

The warrant may help secure a durable customer relationship; it also means the headline contract amount is not the whole economic price.

Sources: Akamai’s Form 8-K; the filed Warrant Agreement; Akamai’s investor presentation; Akamai’s transaction announcement.